CNBX Pharmaceuticals Inc. (CNBX) Stock

About CNBX Pharmaceuticals Inc.

CNBX Pharmaceuticals Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing cannabinoid-based treatments and therapies for various cancers. Its flagship product candidate, RCC-33, is an oral capsule formulation of cannabinoids specifically engineered for treating colorectal cancer. The company's development pipeline also encompasses several other potential drug candidates, including PLP-33, which targets lateral spreading or sessile colorectal polyps during colonoscopy; BRST-33, aimed at breast cancer; MLN-33, designed for melanoma; and PRST-33, intended for prostate cancer. Furthermore, CNBX is developing Cannabics SR, a lipid-based capsule containing a standardized blend of cannabinoids for managing cancer anorexia-cachexia syndrome, alongside Cannabics CDx, an ex-vivo drug sensitivity diagnostic tool. Incorporated in 2004, the company, based in Bethesda, Maryland, was formerly known as Cannabics Pharmaceuticals Inc. before officially changing its name in March 2022. It operates as a subsidiary of Cannabics Inc.

CNBX Pharmaceuticals Inc. (CNBX) stock trades at $0.00 with a market capitalization of $9251. The stock is valued at a price-to-earnings (P/E) ratio of 0.10, price-to-book of -0.05, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, CNBX Pharmaceuticals Inc. generates a return on equity (ROE) of 0.00%, return on capital employed of 16.15%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.cnbxpharma.com